Intellipharmaceutics International Inc
TSX:IPCI
Intellipharmaceutics International Inc
Other
Intellipharmaceutics International Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intellipharmaceutics International Inc
TSX:IPCI
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other
-$105m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
Sundial Growers Inc
NASDAQ:SNDL
|
Other
CA$474k
|
CAGR 3-Years
-85%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Other
-$10.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-74%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other
-$522k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other
-CA$6.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-39%
|
|
Intellipharmaceutics International Inc
Glance View
Intellipharmaceutics International, Inc. is a pharmaceutical company, which engages in the research, development, and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. The company is headquartered in Etobicoke, Ontario. The firm is specializing in the research, development and manufacture of generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products and product candidates in various stages of development, in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its Paradoxical OverDose Resistance Activating System (PODRAS) delivery technology is designed to prevent overdose when more pills than prescribed are swallowed intact. Its product and product candidates include Generic Focalin XR, Generic Keppra XR, Generic Glucophage XR and Generic Effexor XR, among others.
